ADMA - ADMAバイオロジックス （ADMA Biologics Inc）

During the last session, ADMA Biologics Inc. (NASDAQ:ADMA)’s traded shares were 2.98 million, with the beta value of the company hitting 0.87. At the end of the trading day, the stock’s price was $3.42, reflecting an intraday loss of -1.16% or -$0.04. The 52-week high for the ADMA share is $3.98, that puts it down … ADMA Biologics Inc. (NASDAQ: ADMA) Stock Dropped -9.28% Over A Month – Are There Any Chances Of Growth? Read More »

It’s super-easy to look for large-cap stocks – those names that seemingly everyone knows, or FAANG stocks that get plenty of attention from both analysts and retail investors. But if you want to stand out from the crowd and find some bargains with some penny stocks , then this one’s for you. Penny stocks don’t necessarily cost a penny – I don’t think I would be that interested in buying them if they only cost a copper coin. But a true penny stock is anything that’s priced at less than $5 per share. That means that you can pick up plenty of shares of any of these names, for not very much money. Of course, there are some caveats. Penny stocks tend to be more volatile than more so-called “established” stocks, so you have to be comfortable with your risk tolerance. Many times penny stocks are either in their early stages, which means they may not be even making a profit yet. Or they could be companies that fell on hard times and are looking to bounce back. If you’re a retail investor you can probably find plenty of advice about volatile penny stocks on social media, which is fine if that’s the game you want to play.

If you’re not investing in healthcare stocks these days, you may be missing out on a huge opportunity. Consider this: We are getting older and living longer as a species. The World Health Organization says that by 2030, 1 in 6 people on Earth will be at least 60 years old. With an aging population comes more medical issues – either ailments that weaken the bodies or medications and treatments to hold off the aging process as long as possible. We’ll be needing and using more drugs as we get older, will rely more on medical professionals and spend more of our incomes on healthcare. That’s why the time is now to capitalize on this trend. My Portfolio Grader tool evaluated healthcare stocks and identified several with “A” grades based on their recent performance, momentum, analyst sentiment and quantitative factors. Snapping up or adding to your positions in these healthcare stocks could be just what the doctor ordered – if you are hoping to get a little richer, that is. LLY Eli Lilly $345.12 ARDX Ardelyx $3.21 GERN Geron $3.01 ACHC Acadia Healthcare $81.30 ADMA ADMA Biologics $3.85 AMS American Shared Hospital Services $3.20 VMD Viemed Healthcare $8.42 Eli Lilly (LLY) Source: Jonathan Weiss / Shutterstock.com Drugmaker Eli Lilly (NYSE: LLY ) is coming off a strong 2022, where it showed gains of 35%.

ADMA Biologics (ADMA) it had received U.S. Food and Drug Administration approval for its eighth ADMA BioCenters plasma collection facility located in Hammond. The facility is now…

ADMA Biologics (ADMA) added ~3% pre-market Tuesday after pre-announcing its Q4 2022 and full-year financials and setting its 2023 outlook ahead of consensus. Read the full story here.

ADMA Biologics Inc (NASDAQ: ADMA ) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022. The first tranche of the newly issued loan from Hayfin was fully drawn and used to completely repay the obligations under the Perceptive Advisors senior secured notes. As previously disclosed, ADMA has engaged Morgan Stanley (NYSE: MS ) as an advisor … Full story available on Benzinga.com

ADMA Biologics (ADMA) said the U.S. Food and Drug Administration ((FDA)) approved to extend the expiration dating to 36 months from 24 months for its Asceniv and Bivigam immune…

Shares of ADMA Biologics (ADMA) are up 2% in after-hours trading after the company''s Q4 2021 results beat on both the top and bottom lines.

ADMA Biologics press release (ADMA): Q4 GAAP EPS of -$0.09 beats by $0.01.Revenue of $26.38M (+89.0% Y/Y) beats by $4.61M.Shares +3.3%.

ADMA Biologics (ADMA) is scheduled to announce Q4 earnings results on Thursday, March 24th, after market close.The consensus EPS Estimate is -$0.09 (+55.0% Y/Y) and the consensus…

Cantor Fitzgerald initiated coverage on shares of ADMA Biologics (NASDAQ:ADMA) in a report released on Monday morning, The Fly reports. The firm issued an overweight rating on the biotechnology companys stock. A number of other brokerages also recently weighed in on ADMA. Zacks Investment Research upgraded shares of ADMA Biologics from a hold rating to []

Cantor Fitzgerald started coverage on shares of ADMA Biologics (NASDAQ:ADMA) in a research note issued to investors on Monday morning, The Fly reports. The brokerage issued an overweight rating on the biotechnology companys stock. Several other equities research analysts have also issued reports on the company. Raymond James reduced their price target on ADMA Biologics []

ADMA Biologics Inc. (NASDAQ:ADMA) shares, rose in value on Thursday, 11/04/21, with the stock price down by -5.37% to the previous days close as strong demand from buyers drove the stock to $1.41. Actively observing the price movement in the last trading, the stock closed the session at $1.49, falling within a range of $1.37 Analysts Predict A Surge In ADMA Biologics Inc. (NASDAQ: ADMA)? Read More »

Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET

In the last trading session, 3.14 million shares of the ADMA Biologics Inc. (NASDAQ:ADMA) were traded, and its beta was 1.27. Most recently the companys share price was $1.29, and it changed around -$0.05 or -3.73% from the last close, which brings the market valuation of the company to $177.90M. ADMA currently trades at a Why ADMA Biologics Inc. (NASDAQ: ADMA) Stock Should Not Be Taken For Granted By Investors In 2021 Read More »